Form 4: Fulgent Genetics CEO Ming Hsieh Reports Stock Transactions Following RSU Vesting

Fulgent Genetics CEO Ming Hsieh reports acquisition and disposal of company stock related to vesting of performance-based and restricted stock units, as well as tax withholding obligations.

Summary

• On February 25th and 26th, 2025, Ming Hsieh, the CEO of Fulgent Genetics, engaged in several transactions involving the company's common stock.
• These transactions included the acquisition of shares through the vesting of performance-based restricted stock units (RSUs) granted on February 28, 2022, February 23, 2023, and February 26, 2024.
• Hsieh also acquired shares through restricted stock units that vest over three years, starting March 1, 2025.
• Simultaneously, shares were withheld to satisfy tax obligations arising from the vesting of these RSUs.
• The price per share for tax withholding purposes was $16.29 on February 25th and $16.24 on February 26th.
• Following these transactions, Hsieh directly owns 817,078 shares and indirectly owns 8,116,931 shares through various trusts and minor accounts.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine stock transactions related to executive compensation. The vesting of performance-based RSUs is a slightly positive indicator.

Positives

• The vesting of performance-based RSUs suggests the achievement of certain company performance goals.

Future Outlook

Restricted stock units will continue to vest over a three-year period, starting March 1, 2025, subject to continued service.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Vesting of RSUs and subsequent tax withholding are common occurrences.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation mechanisms.

Key Dates